Literature DB >> 7735331

The regulation of DNA topoisomerase II by casein kinase II.

G C Alghisi1, E Roberts, M E Cardenas, S M Gasser.   

Abstract

DNA topoisomerase II is an essential nuclear enzyme required for the proper condensation and segregation of chromosomes during mitotic and meiotic cell division. The enzyme exists in the cell as a phosphoprotein, and it is most highly phosphorylated in G2 and M-phases of the cell cycle. We have shown that topoisomerase II is the target of casein kinase II (CKII) in yeast by comparison of in vivo and in vitro phosphotryptic peptide maps. Limited proteolysis and probing with domain specific antibodies show that with the exception of a weakly modified residue between aa 660 and aa 1250, all residues modified by CKII are in the last 200 amino acids of yeast topoisomerase II. This C-terminal domain is the least conserved region of the enzyme and truncation of the enzyme shows that it is nonessential for activity in vitro. However, the fully dephosphorylated full-size protein is nearly inactive in decatenation assays, and activity can be restored by phosphorylation by CKII. To reconcile these observations, we propose that the C-terminal region is a negative regulatory domain, counteracted by phosphorylation within the domain itself. To test this hypothesis we have mutagenised 12 potential CKII phosphoacceptor sites in the C-terminus of topoisomerase II and introduced the mutant genes into a yeast strain which has a temperature sensitive top2 gene. The growth of the transformed strains is monitored at nonpermissive temperature to determine whether C-terminal phosphorylation is important for mitotic growth. In addition, we have purified the mutant enzymes to homogeneity for in vitro assays.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7735331

Source DB:  PubMed          Journal:  Cell Mol Biol Res        ISSN: 0968-8773


  7 in total

1.  Targeting nucleolin for better survival in diffuse large B-cell lymphoma.

Authors:  N Jain; H Zhu; T Khashab; Q Ye; B George; R Mathur; R K Singh; Z Berkova; J F Wise; F K Braun; X Wang; K Patel; Z Y Xu-Monette; J Courty; K H Young; L Sehgal; F Samaniego
Journal:  Leukemia       Date:  2017-07-10       Impact factor: 11.528

2.  Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation.

Authors:  M J Ciesielski; R A Fenstermaker
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

3.  Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.

Authors:  Y Matsumoto; K Kunishio; S Nagao
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

4.  Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-10

5.  Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-07

6.  Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-07

7.  Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.

Authors:  Y S Vassetzky; G C Alghisi; E Roberts; S M Gasser
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.